NCT04856969View on ClinicalTrials.gov

Clinical Trial to Evaluate Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

March 30, 2021

Primary Completion Date

May 4, 2021

Study Completion Date

May 4, 2021

Conditions
Healthy Adult Volunteers
Interventions
DRUG

Olmesartan

First stage: ATB-1011 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration

DRUG

Dapagliflozin

First stage: ATB-1012 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration

Trial Locations (1)

08779

H Plus Yangji Hospital, Seoul

Sponsors

Lead Sponsor

Autotelicbio
All Listed Sponsors
lead

Autotelicbio

INDUSTRY